Hydrochlorothiazide Orifarm (Hydrochlorothiazide)

Hydrochlorothiazide Orifarm is prescribed for several conditions where reduction of excess fluid or blood pressure is required.

• Hypertension (high blood pressure) management, either alone or in combination with other antihypertensive agents.
• Edema associated with congestive heart failure, helping to remove excess fluid and reduce cardiac workload.
• Ascites and peripheral edema related to hepatic cirrhosis, facilitating sodium and water excretion.
• Fluid retention caused by renal disorders such as nephrotic syndrome, supporting diuresis.

• Hydrochlorothiazide Orifarm acts by inhibiting the sodium‑chloride symporter in the distal convoluted tubule of the nephron. This blockade reduces Na⁺ and Cl⁻ reabsorption, leading to increased urinary excretion of sodium, chloride, and water (natriuresis and diuresis). The resulting decrease in extracellular fluid volume lowers systemic vascular resistance and cardiac output, contributing to blood pressure reduction. The effect begins within a few hours after oral intake and persists for up to 24 hours, allowing once‑daily dosing in many patients.

Like other thiazide diuretics, Hydrochlorothiazide Orifarm may cause a range of adverse reactions, most of which are mild and dose‑related.

Common

• Increased urination, especially during the first few days of therapy.
• Electrolyte disturbances such as low potassium (hypokalemia) or low sodium (hyponatremia).
• Elevated blood glucose levels, which may be relevant for patients with diabetes.
• Mild dizziness or headache due to volume depletion.

Serious

• Severe electrolyte imbalance leading to arrhythmias or muscle weakness.
• Acute gout attacks triggered by elevated uric acid.
• Allergic reactions including rash, pruritus, or, rarely, angioedema.

Before initiating Hydrochlorothiazide Orifarm, clinicians should evaluate several safety considerations to minimize risk.

• Assess renal function; avoid use in patients with severe impairment or anuria.
• Monitor serum electrolytes, particularly potassium and sodium, during treatment.
• Use cautiously in individuals with a history of gout or hyperuricemia.
• Consider the potential for increased blood glucose; monitor diabetic patients closely.
• Evaluate for sulfonamide allergy, as hydrochlorothiazide is a sulfonamide derivative.
• Advise patients to rise slowly from sitting or lying positions to reduce orthostatic hypotension.
• Pregnancy category B indicates limited data; use only when benefit outweighs potential risk.

Hydrochlorothiazide Orifarm can interact with several medicines, altering its efficacy or safety profile.

Avoid

• Lithium, because thiazides can increase lithium levels and risk toxicity.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs), which may blunt diuretic effect and impair renal function.
• Cyclosporine or tacrolimus, as combined use can exacerbate nephrotoxicity.

Use with caution

• ACE inhibitors, ARBs, or beta‑blockers; concurrent use may enhance hypotensive effect.
• Antidiabetic agents; diuretic‑induced changes in glucose may require dose adjustment.
• Digoxin; electrolyte shifts, especially low potassium, can increase digoxin toxicity risk.